keyword
https://read.qxmd.com/read/36900229/efficiency-and-safety-of-cyberknife-robotic-radiosurgery-in-the-multimodal-management-of-patients-with-acromegaly
#21
JOURNAL ARTICLE
Carlos Alfonso Romero-Gameros, Baldomero González-Virla, Guadalupe Vargas-Ortega, Ernesto Sosa-Eroza, Mario Enrique Rendón-Macías, Lourdes Josefina Balcázar-Hernández, Moises Mercado, Novelthys Velasco-Cortes, Carlos Aaron Rodea-Ávila, Luis Flores-Robles, José Armando Lorenzana-Hernández, José Vázquez-Rojas, Margarita López-Palma
OBJECTIVE: To analyze, in a cohort of acromegalic patients, the results of the efficiency and safety of radiosurgery (CyberKnife), as well as the prognostic factors associated with disease remission. MATERIAL AND METHODS: Observational, retrospective, longitudinal, and analytical study that included acromegalic patients with persistent biochemical activity after initial medical-surgical treatment, who received treatment with CyberKnife radiosurgery. GH and IGF-1 levels at baseline after one year and at the end of follow-up were evaluated...
February 24, 2023: Cancers
https://read.qxmd.com/read/36877453/autonomous-growth-hormone-secretion-due-to-mccune-albright-syndrome-in-paediatric-age-group-an-ominous-triad
#22
JOURNAL ARTICLE
Satyam Singh Jayant, Rama Walia, Rahul Gupta, Rimesh Pal, Shakun Chaudhary, Kanhaiya Agrawal, Ashu Rastogi, Anish Bhattacharya, Pinaki Dutta, Sanjay Kumar Bhadada, Anil Bhansali
PURPOSE: The current study aimed to report cases of McCune Albright syndrome (MAS) with growth hormone (GH) hyper secretion along with a systematic review of literature to elucidate challenges and intricacies in its diagnosis and management. METHODS: It was a single centre study carried out in individuals with MAS and autonomous GH secretion (AGHS). In addition, a systematic search of literature across three databases (PubMed, Scopus and EMBASE) was performed from inception until May 31, 2021 to identify cases of MAS with AGHS in the pediatric age group (<18 years)...
March 6, 2023: Endocrine
https://read.qxmd.com/read/36774403/cystic-versus-non-cystic-silent-corticotrophic-adenomas-clinical-and-histological-analysis-of-62-cases-after-microscopic-transsphenoidal-surgery-a-retrospective-single-center-study
#23
JOURNAL ARTICLE
Piotr Sumislawski, Torge Huckhagel, Kara Leigh Krajewski, Jens Aberle, Wolfgang Saeger, Jörg Flitsch, Roman Rotermund
Silent corticotrophic adenomas (SCAs) represent a rare group of non-functioning adenomas with a potentially aggressive clinical course. Cystic component is a very common finding among SCAs, but its clinical relevance has not yet been investigated. The aim of this study was to analyze clinical features of cystic and non-cystic SCAs, perioperative complications after microscopic transsphenoidal surgery, clinical outcome after first and repeat surgery along with risk factors for recurrence. We conducted a retrospective analysis of 62 silent corticotrophic adenomas treated at our university medical center via microscopic transsphenoidal surgery between January 2008 and July 2019...
February 11, 2023: Scientific Reports
https://read.qxmd.com/read/36743656/growth-hormone-and-gastrointestinal-malignancy-an-intriguing-link
#24
REVIEW
Rajan Palui, Kalyani Sridharan, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Dukhabandhu Naik
Growth hormone (GH) excess is associated with several systemic complications, one of which is the increased risk of neoplastic processes particularly of the gastrointestinal (GI) tract. Among the GI neoplasms, the most reported association is with benign and malignant neoplasms of the colon. In the majority of published literature, an increased incidence of GI neoplasms, both colonic adenomas as well as colorectal carcinoma is reported. However, the studies on colon cancer-specific mortality rate are conflicting with recent studies reporting similar cancer-specific mortality rates in comparison to controls...
January 22, 2023: World Journal of Gastrointestinal Pathophysiology
https://read.qxmd.com/read/36689713/-short-term-and-long-term-remission-after-endoscopic-transnasal-adenomectomy-in-patients-with-acromegaly
#25
JOURNAL ARTICLE
A S Lutsenko, Zh E Belaya, E G Przhiyalkovskaya, A M Lapshina, A G Nikitin, V N Azizyan, O V Ivaschenko, A Yu Grigoriev, G A Melnichenko
BACKGROUND: Neurosurgery is the most effective treatment for acromegaly. As most of the patients present with macroadenomas, surgical treatment is not always successful, even with the expert level of a neurosurgeon. Assessment of the postoperative remission rates in acromegaly preoperative predictors of treatment efficacy is an urgent task of modern research. AIM: To assess the short-term and long-term remission of acromegaly after endoscopic transnasal adenomectomy in a tertiary medical center and assess preoperative predictors of the treatment effectiveness...
November 24, 2022: Problemy E̊ndokrinologii
https://read.qxmd.com/read/36612263/the-prognostic-based-approach-in-growth-hormone-secreting-pituitary-neuroendocrine-tumors-pitnet-tertiary-reference-center-single-senior-surgeon-and-long-term-follow-up
#26
JOURNAL ARTICLE
Abel Ferrés, Luís Reyes, Alberto Di Somma, Thomaz Topczewski, Alejandra Mosteiro, Giulia Guizzardi, Andrea De Rosa, Irene Halperin, Felicia Hanzu, Mireia Mora, Isam Alobid, Iban Aldecoa, Núria Bargalló, Joaquim Enseñat
Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]...
December 30, 2022: Cancers
https://read.qxmd.com/read/36539773/pleiomorphism-plurihormonal-pit-1-positive-macroadenoma-with-central-hyperthyroidism-a-rare-case-report-and-literature-review
#27
JOURNAL ARTICLE
Guiliang Peng, Chuanhong Guo, Yangfan Lv, Dandan Li, Ling Zhou, Rufei Shen, Yong Chen, Xin Zheng, Zheng Sun, Hongting Zheng, Min Long
BACKGROUND: Thyrotropin-secreting pituitary neuroendocrine tumors (PitNETs) are rare pituitary adenomas that are occasionally accompanied by hypersecretion of other anterior pituitary hormones, such as growth hormone (GH) and prolactin (PRL). The clinical, biochemical, and pathological characteristics may represent diverse circumstances. CASE PRESENTATION: In this report, a 33-year-old female diagnosed with a TSH PitNET co-secreting GH presented no obvious clinical symptoms...
December 21, 2022: BMC Endocrine Disorders
https://read.qxmd.com/read/36335516/gigantism-microsurgical-treatment-by-transsphenoidal-approach-and-prognostic-factors
#28
JOURNAL ARTICLE
María García-Uría Santos, Cecilia Fernández Mateos, Tomás Lucas Morante, José García-Uría
PURPOSE: We present the results of transsphenoidal microsurgical treatment in 14 patients with gigantism. The influence on the prognosis of factors such as the tumor size and preoperative levels of GH and IGF-1 is also quantified. MATERIALS AND METHODS: The patients, operated between 1982 and 2004, were reviewed retrospectively in June 2022. All patients had complete endocrinological studies in the preoperative period and a postoperative control between 6 days and 3 weeks...
November 6, 2022: Pituitary
https://read.qxmd.com/read/36318446/giant-growh-hormone-secreting-pituitary-adenomas-from-the-endocrinologist-s-perspective
#29
JOURNAL ARTICLE
Bahadir Koylu, Busra Firlatan, Suleyman Nahit Sendur, Seda Hanife Oguz, Selcuk Dagdelen, Tomris Erbas
OBJECTIVES: Since giant (≥40 mm) GH-secreting pituitary adenomas are rarely encountered, data on their characteristics and treatment outcomes are limited. We aimed to investigate the characteristics of giant GH-secreting pituitary adenomas and to compare their clinical, biochemical, imaging and histopathological features with non-giant macroadenomas. MATERIALS AND METHODS: We have evaluated 15 (six female/nine male) and 57 (29 female/28 male) patients with acromegaly in giant and <40 mm adenoma groups, respectively...
November 1, 2022: Endocrine
https://read.qxmd.com/read/36285746/may-the-sagit%C3%A2-instrument-be-used-as-a-preoperative-prognostic-tool-in-patients-with-acromegaly
#30
JOURNAL ARTICLE
Emre Gezer, Berrin Çetinarslan, Zeynep Cantürk, Alev Selek, Mehmet Sözen, Damla Köksalan, Aylin Bekiroğlu, Ihsan Anik, Savaş Ceylan
BACKGROUND: The SAGIT® instrument has been developed for acromegaly to assist clinicians in staging the disease accurately, assessing the response to therapy, and adjusting the treatment. We aimed to evaluate the preoperative utility of the SAGIT® instrument and to discover a cut-off value for predicting the surgery outcome and long-term prognosis of patients with acromegaly. METHODS: A total of 832 patients with acromegaly were identified from the medical record system...
October 26, 2022: Minerva endocrinology
https://read.qxmd.com/read/36198614/self-reported-symptoms-in-patients-with-acromegaly-a-6-month-follow-up-in-a-single-neurosurgical-center
#31
JOURNAL ARTICLE
Ben Lin, Wenqiang He, Zhengyuan Chen, Ming Shen, Xuefei Shou, Long Chen, Zengyi Ma, Yongfei Wang
Acromegaly is characterized by hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), accompanied by a compromise in the perception of wellness. The Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) is relevant to assessing signs and symptoms but is mainly used to evaluate the efficacy of a pharmacological intervention. To explore the perioperative variation in symptom severity, the divergence between subgroups stratified according to clinical outcomes or treatment modalities, and the interaction between symptom scores and clinical indices, we prospectively recruited 106 patients with acromegaly from 2016 to 2018...
October 5, 2022: Endocrine Journal
https://read.qxmd.com/read/36187107/factors-associated-with-therapeutic-response-in-acromegaly-diagnosed-in-the-elderly-in-spain
#32
JOURNAL ARTICLE
Betina Biagetti, Pedro Iglesias, Rocío Villar-Taibo, María-Dolores Moure, Miguel Paja, Marta Araujo-Castro, Jessica Ares, Cristina Álvarez-Escola, Almudena Vicente, Èlia Álvarez Guivernau, Iria Novoa-Testa, Fernando Guerrero Perez, Rosa Cámara, Beatriz Lecumberri, Carlos García Gómez, Ignacio Bernabéu, Laura Manjón, Sonia Gaztambide, Fernando Cordido, Susan M Webb, Edelmiro Luis Menéndez-Torre, Juan J Díez, Rafael Simó, Manel Puig-Domingo
Context: Some reports suggest that acromegaly in elderly patients has a more benign clinical behavior and could have a better response to first-generation long-acting somatostatin receptor ligands (SRL). However, there is no specific therapeutic protocol for this special subgroup of patients. Objective: This study aimed at identifying predictors of response to SRL in elderly patients. Design: Multicentric retrospective nationwide study of patients diagnosed with acromegaly at or over the age of 65 years...
2022: Frontiers in Endocrinology
https://read.qxmd.com/read/36187106/clinical-hormonal-and-pathomorphological-markers-of-somatotroph-pituitary-neuroendocrine-tumors-predicting-the-treatment-outcome-in-acromegaly
#33
JOURNAL ARTICLE
Agnieszka Tomasik, Maria Stelmachowska-Banaś, Maria Maksymowicz, Izabella Czajka-Oraniec, Dorota Raczkiewicz, Grzegorz Zieliński, Jacek Kunicki, Wojciech Zgliczyński
Background: Transsphenoidal adenomectomy (TSS) of somatotroph pituitary neuroendocrine tumor (PitNET) is the first-line treatment of acromegaly. Pharmacological treatment is recommended if surgery is contraindicated or did not lead to disease remission. The choice of treatment best fitting each patient should be based on thorough investigation of patients' characteristics. The current analysis attempts to create a tool for personalized treatment planning. Aim: This study aimed to assess whether clinical, biochemical, imaging and pathological characteristics can predict surgical remission and response to first-generation somatostatin receptor ligands (SRLs) and pasireotide-LAR in acromegaly...
2022: Frontiers in Endocrinology
https://read.qxmd.com/read/36066988/assessment-of-right-ventricular-functions-in-acromegaly-comparison-of-active-disease-with-remission
#34
JOURNAL ARTICLE
Osman Pirhan, Abdülcelil Sait Ertuğrul, Cennet Yıldız, Dilay Karabulut, Bahar Pehlivan, Hamide Piskinpasa, Sema Ciftci Dogansen, Meral Mert
Aim    Cardiac involvement in acromegaly is defined as acromegalic cardiomyopathy, an insidious and chronic disease. Previous research on acromegalic cardiomyopathy was largely focused on morphological and functional assessment of the left heart. Since the literature data regarding right heart function in acromegalic patients are limited, we aimed to evaluate the structure and function of the right heart in such patients.Material and Methods    We included 43 adult participants as the acromegaly group and 42 individuals as the control group...
August 30, 2022: Kardiologiia
https://read.qxmd.com/read/36042253/association-of-pre-and-postoperative-%C3%AE-klotho-levels-with-long-term-remission-after-pituitary-surgery-for-acromegaly
#35
JOURNAL ARTICLE
Marian Christoph Neidert, Anna Maria Zeitlberger, Henning Leske, Oliver Tschopp, Lisa Sze, Cornelia Zwimpfer, Peter Wiesli, David Bellut, René-Ludwig Bernays, Elisabeth Jane Rushing, Christoph Schmid
Soluble αKlotho (sKl) is a disease-specific biomarker that is elevated in patients with acromegaly and declines after surgery for pituitary adenoma. Approximately 25% of patients do not achieve remission after surgery, therefore a risk stratification for patients early in the course of their disease may allow for the identification of patients requiring adjuvant treatment. Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) have been assessed as biomarker for disease activity, however the value of sKl as a predictive biomarker of surgical success has not been evaluated yet...
August 30, 2022: Scientific Reports
https://read.qxmd.com/read/35992136/surgery-for-acromegaly-indications-and-goals
#36
REVIEW
David P Bray, Sai Mannam, Rima S Rindler, Joseph W Quillin, Nelson M Oyesiku
Acromegaly is a disease that occurs secondary to high levels of GH, most often from a hormone-secreting pituitary adenoma, with multisystem adverse effects. Diagnosis includes serum GH and IGF-1 levels, and obtaining an MRI pituitary protocol to assess for a functional pituitary adenoma. Attempted gross total resection of the GH-secreting adenoma is the gold standard in treatment for patients with acromegaly for a goal of biochemical remission. Medical and radiation therapies are available when patients do not achieve biochemical cure after surgical therapy...
2022: Frontiers in Endocrinology
https://read.qxmd.com/read/35965944/preoperative-medical-treatment-for-patients-with-acromegaly-yes-or-no
#37
REVIEW
Frederique Albarel, Thomas Cuny, Thomas Graillon, Henry Dufour, Thierry Brue, Frederic Castinetti
Transsphenoidal surgery is the first-line treatment for acromegaly. However, several factors can modify surgical remission rates, such as the initial hormone levels, the size and invasiveness of the tumor, and the degree of experience of the surgeon. Physicians treating patients with acromegaly should thus consider how to improve surgical remission rates. As stated in recent guidelines, the major point is to consider that any patient with acromegaly should be referred to an expert neurosurgeon to maximize the chances of surgical sure...
September 1, 2022: Journal of the Endocrine Society
https://read.qxmd.com/read/35959088/sparsely-granulated-corticotroph-pituitary-macroadenoma-presenting-with-pituitary-apoplexy-resulting-in-remission-of-hypercortisolism
#38
Tao Liu, John P Rossiter, Robyn L Houlden, Sara Awad
Objective: Pituitary corticotroph macroadenomas, which account for 7% to 23% of corticotroph adenomas, rarely present with apoplexy. This report aimed to describe a patient with a sparsely granulated corticotroph tumor (SGCT) presenting with apoplexy and remission of hypercortisolism. Case Report: A 33-year-old male patient presented via ambulance with sudden onset of severe headache and nausea/vomiting. Physical examination revealed bitemporal hemianopsia, diplopia from right-sided third cranial nerve palsy, abdominal striae, facial plethora, and dorsal and supraclavicular fat pads...
July 2022: AACE Clinical Case Reports
https://read.qxmd.com/read/35796476/-acromegaly-an-endocrine-pathology-with-serious-consequences
#39
JOURNAL ARTICLE
Afef Horchani, Ines Bayar, Bilel Ben Amor, Ilhem Hellara, Mabrouk Abdelali, Fadoua Neffati, Ines Khochtali, Mohamed Fadhel Najjar
Acromegaly is a rare endocrine disorder leading to an acquired physical disfigurement and multisystem damage. It is caused in over 95% of cases by a secreting pituitary adenoma. Latency period between disease onset and diagnosis is mainly 10 years due to progressive chronic evolution and exposure to high levels of GH and IGF-1. Here we present a case of acromegaly with over 25 years of diagnostic delay in 69-years-old male with typical features and recurrent urolithiasis. Biochemical diagnosis was confirmed by high levels of IGF-1and lack of suppression of GH during an oral glucose load...
June 30, 2022: Annales de Biologie Clinique
https://read.qxmd.com/read/35732439/subclinical-acromegaly-to-treat-or-not-to-treat
#40
JOURNAL ARTICLE
Ilan Shimon, Zaina Adnan, Dania Hirsch, Hadar Duskin-Bitan, Amit Akirov
Patients with acromegaly usually present with the classical signs of acromegaly, whereas patients without the specific signs or symptoms are rarely diagnosed. This unique entity can be named "subclinical acromegaly". This was a retrospective study. Our study group consisted of 6 patients (4 females) with incidentally diagnosed acromegaly, most following head MRI for unrelated reasons and without the specific signs of acromegaly. Mean age at diagnosis was 48.8 ± 19.2 years. Baseline IGF-1 ranged between 1...
November 28, 2022: Endocrine Journal
keyword
keyword
162383
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.